Drug Profile
Research programme: macular degeneration therapy - Columbia University/MultiCell Technologies
Alternative Names: MCT-355Latest Information Update: 08 Jun 2010
Price :
$50
*
At a glance
- Originator Columbia University; MultiCell Technologies Inc
- Class Small molecules
- Mechanism of Action Apoptosis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Macular degeneration
Most Recent Events
- 12 Dec 2005 Preclinical trials in Macular degeneration in USA (unspecified route)